Profile
From: WHO, 2015. Myanmar Malaria Profile. Geneva: World Health Organization. Available at: www.who.int
Epidemiological profile of Myanmar
| Population by malaria endemicity (000) | 2015 | % |
|---|---|---|
| High transmission (≥ 1 case per 1000 population) | 8 520 | 16 |
| Low transmission (0-1 cases per 1000 population) | 23 600 | 44 |
| Malaria free (0 cases) | 21 800 | 40 |
| Total | 53 900 |
| Parasites and vectors | |
|---|---|
| Major plasmodium species | P. falciparum (66%), P. vivax (34%) |
| Major anopheles species | An. dirus, minimus |
Intervention policies and strategies
| Intervention | WHO-recommended policy/strategy | Yes/no | Year adopted |
|---|---|---|---|
| ITN/LLIN |
ITNs/LLINs distributed free of charge ITNs/LLINs distributed to all age groups |
Yes Yes |
2000 2000 |
| IRS |
IRS is recommended DDT is used for IRS |
Yes No |
1957 - |
| IPT | IPT is used to prevent malaria during pregnancy | N/A | |
| Case management |
Patients of all ages should receive diagnostic test RDTs used at community level ACT is free for all ages in public sector Pre-referral treatment with recommended medicines Oral artemisinin-based monotherapies are not registered |
Yes Yes Yes Yes Yes |
1962 2007 2003 2004 -- |
| Antimalarial policy | Type of medicine | Year adopted |
|---|---|---|
| First-line treatment of unconfirmed malaria | - | - |
| First-line treatment of P.falciparum | AL; AM; AS+MQ; DHA-PPQ; PQ | 2008 |
| For treatment failure of P.falciparum | AS+D; AS+T | 2008 |
| Treatment of severe malaria | AM; AS; QN | 2008 |
| Treatment of P.vivax | CQ+PQ(14d) | 2008 |
Therapeutic efficacity tests (therapeutic or parasitological failure, %)
| Medicine | Year | No. of studies | Min. | Median | Max. | Follow-up |
| AL | 2007-2015 | 25 | 0 | 1.9 | 6 | 28 days |
| AS+MQ | 2011-2013 | 5 | 0 | 0 | 2.2 | 42 days |
| DHA-PPQ | 2007-2011 | 12 | 0 | 1.6 | 5 | 28 days |
